nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—ABCC2—type 2 diabetes mellitus	0.0948	0.334	CbGaD
Sorafenib—HTR2C—type 2 diabetes mellitus	0.0838	0.295	CbGaD
Sorafenib—CYP1A2—type 2 diabetes mellitus	0.0633	0.223	CbGaD
Sorafenib—CYP3A4—type 2 diabetes mellitus	0.0419	0.148	CbGaD
Sorafenib—UGT1A9—Nateglinide—type 2 diabetes mellitus	0.0264	0.066	CbGbCtD
Sorafenib—ABCC4—Nateglinide—type 2 diabetes mellitus	0.0221	0.0552	CbGbCtD
Sorafenib—HTR2B—Bromocriptine—type 2 diabetes mellitus	0.0188	0.0469	CbGbCtD
Sorafenib—UGT1A1—Losartan—type 2 diabetes mellitus	0.0134	0.0334	CbGbCtD
Sorafenib—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.0122	0.0305	CbGbCtD
Sorafenib—CYP2C8—Sitagliptin—type 2 diabetes mellitus	0.0116	0.0289	CbGbCtD
Sorafenib—CYP2C8—Repaglinide—type 2 diabetes mellitus	0.00925	0.0231	CbGbCtD
Sorafenib—ABCC2—Glyburide—type 2 diabetes mellitus	0.00889	0.0222	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Nateglinide—type 2 diabetes mellitus	0.00879	0.0219	CbGbCtD
Sorafenib—CYP3A7—Nateglinide—type 2 diabetes mellitus	0.00879	0.0219	CbGbCtD
Sorafenib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.00878	0.0219	CbGbCtD
Sorafenib—CYP2C8—Pioglitazone—type 2 diabetes mellitus	0.00836	0.0209	CbGbCtD
Sorafenib—CYP2C19—Gliclazide—type 2 diabetes mellitus	0.00825	0.0206	CbGbCtD
Sorafenib—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.00807	0.0201	CbGbCtD
Sorafenib—ABCG2—Glyburide—type 2 diabetes mellitus	0.00804	0.0201	CbGbCtD
Sorafenib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.00783	0.0195	CbGbCtD
Sorafenib—CYP2C8—Rosiglitazone—type 2 diabetes mellitus	0.00772	0.0193	CbGbCtD
Sorafenib—CYP2C8—Tolbutamide—type 2 diabetes mellitus	0.00745	0.0186	CbGbCtD
Sorafenib—CYP2C9—Glipizide—type 2 diabetes mellitus	0.00738	0.0184	CbGbCtD
Sorafenib—CYP2C19—Pioglitazone—type 2 diabetes mellitus	0.00702	0.0175	CbGbCtD
Sorafenib—CYP2C19—Chlorpropamide—type 2 diabetes mellitus	0.00702	0.0175	CbGbCtD
Sorafenib—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.00686	0.0171	CbGbCtD
Sorafenib—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.00659	0.0165	CbGbCtD
Sorafenib—CYP2C19—Rosiglitazone—type 2 diabetes mellitus	0.00647	0.0162	CbGbCtD
Sorafenib—CYP2C19—Tolbutamide—type 2 diabetes mellitus	0.00625	0.0156	CbGbCtD
Sorafenib—CYP2C8—Irbesartan—type 2 diabetes mellitus	0.00608	0.0152	CbGbCtD
Sorafenib—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.00597	0.0149	CbGbCtD
Sorafenib—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.00583	0.0146	CbGbCtD
Sorafenib—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.00583	0.0146	CbGbCtD
Sorafenib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00566	0.0141	CbGbCtD
Sorafenib—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.00538	0.0134	CbGbCtD
Sorafenib—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00533	0.0133	CbGbCtD
Sorafenib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00526	0.0131	CbGbCtD
Sorafenib—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.0052	0.013	CbGbCtD
Sorafenib—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00492	0.0123	CbGbCtD
Sorafenib—CYP2C9—Valsartan—type 2 diabetes mellitus	0.00475	0.0119	CbGbCtD
Sorafenib—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.0047	0.0117	CbGbCtD
Sorafenib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00469	0.0117	CbGbCtD
Sorafenib—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00445	0.0111	CbGbCtD
Sorafenib—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.00442	0.011	CbGbCtD
Sorafenib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00429	0.0107	CbGbCtD
Sorafenib—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.00424	0.0106	CbGbCtD
Sorafenib—CYP3A5—Losartan—type 2 diabetes mellitus	0.00407	0.0102	CbGbCtD
Sorafenib—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.00404	0.0101	CbGbCtD
Sorafenib—CYP2C8—Losartan—type 2 diabetes mellitus	0.00392	0.00977	CbGbCtD
Sorafenib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00389	0.00971	CbGbCtD
Sorafenib—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00388	0.00967	CbGbCtD
Sorafenib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00375	0.00936	CbGbCtD
Sorafenib—CYP2C19—Glyburide—type 2 diabetes mellitus	0.00359	0.00897	CbGbCtD
Sorafenib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00339	0.00847	CbGbCtD
Sorafenib—CYP2C19—Losartan—type 2 diabetes mellitus	0.00328	0.0082	CbGbCtD
Sorafenib—CYP1A2—Losartan—type 2 diabetes mellitus	0.00303	0.00757	CbGbCtD
Sorafenib—CYP2C9—Glyburide—type 2 diabetes mellitus	0.00299	0.00745	CbGbCtD
Sorafenib—ABCB1—Glyburide—type 2 diabetes mellitus	0.0029	0.00723	CbGbCtD
Sorafenib—CYP2C9—Losartan—type 2 diabetes mellitus	0.00273	0.00682	CbGbCtD
Sorafenib—ABCB1—Losartan—type 2 diabetes mellitus	0.00265	0.00662	CbGbCtD
Sorafenib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00257	0.00642	CbGbCtD
Sorafenib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00246	0.00615	CbGbCtD
Sorafenib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00246	0.00615	CbGbCtD
Sorafenib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00233	0.00582	CbGbCtD
Sorafenib—PDGFRA—penis—type 2 diabetes mellitus	0.00189	0.0308	CbGeAlD
Sorafenib—RET—autonomic nervous system—type 2 diabetes mellitus	0.00187	0.0304	CbGeAlD
Sorafenib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00174	0.00433	CbGbCtD
Sorafenib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00159	0.00396	CbGbCtD
Sorafenib—CDKL3—cardiovascular system—type 2 diabetes mellitus	0.00133	0.0216	CbGeAlD
Sorafenib—KDR—hindlimb—type 2 diabetes mellitus	0.00129	0.021	CbGeAlD
Sorafenib—TIE1—endothelium—type 2 diabetes mellitus	0.00123	0.02	CbGeAlD
Sorafenib—CDKL3—adipose tissue—type 2 diabetes mellitus	0.00117	0.0191	CbGeAlD
Sorafenib—FLT4—endothelium—type 2 diabetes mellitus	0.00101	0.0165	CbGeAlD
Sorafenib—FLT1—artery—type 2 diabetes mellitus	0.000934	0.0152	CbGeAlD
Sorafenib—KDR—artery—type 2 diabetes mellitus	0.000789	0.0128	CbGeAlD
Sorafenib—FLT1—endothelium—type 2 diabetes mellitus	0.000789	0.0128	CbGeAlD
Sorafenib—HIPK3—islet of Langerhans—type 2 diabetes mellitus	0.000747	0.0122	CbGeAlD
Sorafenib—KDR—endothelium—type 2 diabetes mellitus	0.000667	0.0109	CbGeAlD
Sorafenib—HIPK3—retina—type 2 diabetes mellitus	0.000639	0.0104	CbGeAlD
Sorafenib—HIPK3—nephron tubule—type 2 diabetes mellitus	0.000602	0.00979	CbGeAlD
Sorafenib—KIT—endothelium—type 2 diabetes mellitus	0.000591	0.00962	CbGeAlD
Sorafenib—MAPK11—adipose tissue—type 2 diabetes mellitus	0.000573	0.00932	CbGeAlD
Sorafenib—CDK7—adipose tissue—type 2 diabetes mellitus	0.000563	0.00917	CbGeAlD
Sorafenib—TAOK2—adipose tissue—type 2 diabetes mellitus	0.000559	0.0091	CbGeAlD
Sorafenib—ZAK—cardiovascular system—type 2 diabetes mellitus	0.000552	0.00899	CbGeAlD
Sorafenib—EPHX2—retina—type 2 diabetes mellitus	0.000547	0.0089	CbGeAlD
Sorafenib—HIPK3—cardiovascular system—type 2 diabetes mellitus	0.00054	0.00879	CbGeAlD
Sorafenib—HIPK3—kidney—type 2 diabetes mellitus	0.000529	0.0086	CbGeAlD
Sorafenib—HIPK3—pancreas—type 2 diabetes mellitus	0.000525	0.00855	CbGeAlD
Sorafenib—MKNK2—islet of Langerhans—type 2 diabetes mellitus	0.000522	0.0085	CbGeAlD
Sorafenib—EPHX2—nephron tubule—type 2 diabetes mellitus	0.000515	0.00838	CbGeAlD
Sorafenib—TIE1—cardiovascular system—type 2 diabetes mellitus	0.000505	0.00822	CbGeAlD
Sorafenib—ZAK—adipose tissue—type 2 diabetes mellitus	0.000487	0.00792	CbGeAlD
Sorafenib—HIPK3—adipose tissue—type 2 diabetes mellitus	0.000476	0.00775	CbGeAlD
Sorafenib—RALBP1—islet of Langerhans—type 2 diabetes mellitus	0.000472	0.00768	CbGeAlD
Sorafenib—MAP3K7—retina—type 2 diabetes mellitus	0.000461	0.0075	CbGeAlD
Sorafenib—FLT3—cardiovascular system—type 2 diabetes mellitus	0.000459	0.00748	CbGeAlD
Sorafenib—FLT1—islet of Langerhans—type 2 diabetes mellitus	0.000449	0.0073	CbGeAlD
Sorafenib—MKNK2—retina—type 2 diabetes mellitus	0.000446	0.00727	CbGeAlD
Sorafenib—RAF1—islet of Langerhans—type 2 diabetes mellitus	0.000446	0.00726	CbGeAlD
Sorafenib—TIE1—adipose tissue—type 2 diabetes mellitus	0.000445	0.00725	CbGeAlD
Sorafenib—EPHB6—islet of Langerhans—type 2 diabetes mellitus	0.000443	0.00722	CbGeAlD
Sorafenib—MKNK1—retina—type 2 diabetes mellitus	0.000441	0.00718	CbGeAlD
Sorafenib—EPHX2—cortex of kidney—type 2 diabetes mellitus	0.000441	0.00718	CbGeAlD
Sorafenib—BRAF—adipose tissue—type 2 diabetes mellitus	0.000427	0.00695	CbGeAlD
Sorafenib—MKNK2—nephron tubule—type 2 diabetes mellitus	0.00042	0.00684	CbGeAlD
Sorafenib—FLT4—cardiovascular system—type 2 diabetes mellitus	0.000417	0.00679	CbGeAlD
Sorafenib—UGT1A9—kidney—type 2 diabetes mellitus	0.000414	0.00674	CbGeAlD
Sorafenib—EPHX2—adipose tissue—type 2 diabetes mellitus	0.000408	0.00664	CbGeAlD
Sorafenib—RALBP1—retina—type 2 diabetes mellitus	0.000403	0.00656	CbGeAlD
Sorafenib—Regorafenib—CYP3A4—type 2 diabetes mellitus	0.000402	0.402	CrCbGaD
Sorafenib—FLT4—cortex of kidney—type 2 diabetes mellitus	0.000398	0.00647	CbGeAlD
Sorafenib—CDK7—liver—type 2 diabetes mellitus	0.000395	0.00643	CbGeAlD
Sorafenib—FGFR1—cortex of kidney—type 2 diabetes mellitus	0.000392	0.00638	CbGeAlD
Sorafenib—TAOK2—liver—type 2 diabetes mellitus	0.000392	0.00638	CbGeAlD
Sorafenib—FLT1—retina—type 2 diabetes mellitus	0.000384	0.00624	CbGeAlD
Sorafenib—RALBP1—nephron tubule—type 2 diabetes mellitus	0.00038	0.00618	CbGeAlD
Sorafenib—MKNK2—cardiovascular system—type 2 diabetes mellitus	0.000378	0.00615	CbGeAlD
Sorafenib—MKNK1—cardiovascular system—type 2 diabetes mellitus	0.000373	0.00607	CbGeAlD
Sorafenib—MAP3K7—cortex of kidney—type 2 diabetes mellitus	0.000371	0.00604	CbGeAlD
Sorafenib—FLT4—adipose tissue—type 2 diabetes mellitus	0.000368	0.00599	CbGeAlD
Sorafenib—MKNK2—pancreas—type 2 diabetes mellitus	0.000367	0.00598	CbGeAlD
Sorafenib—FGFR1—adipose tissue—type 2 diabetes mellitus	0.000363	0.00591	CbGeAlD
Sorafenib—FLT1—nephron tubule—type 2 diabetes mellitus	0.000361	0.00588	CbGeAlD
Sorafenib—RET—kidney—type 2 diabetes mellitus	0.00036	0.00587	CbGeAlD
Sorafenib—MKNK2—cortex of kidney—type 2 diabetes mellitus	0.00036	0.00586	CbGeAlD
Sorafenib—RAF1—nephron tubule—type 2 diabetes mellitus	0.000359	0.00584	CbGeAlD
Sorafenib—MKNK1—cortex of kidney—type 2 diabetes mellitus	0.000355	0.00578	CbGeAlD
Sorafenib—MAP3K7—adipose tissue—type 2 diabetes mellitus	0.000344	0.00559	CbGeAlD
Sorafenib—ZAK—liver—type 2 diabetes mellitus	0.000341	0.00556	CbGeAlD
Sorafenib—RALBP1—cardiovascular system—type 2 diabetes mellitus	0.000341	0.00555	CbGeAlD
Sorafenib—HIPK3—liver—type 2 diabetes mellitus	0.000334	0.00544	CbGeAlD
Sorafenib—RALBP1—kidney—type 2 diabetes mellitus	0.000334	0.00543	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—nephron tubule—type 2 diabetes mellitus	0.000333	0.00542	CbGeAlD
Sorafenib—MKNK2—adipose tissue—type 2 diabetes mellitus	0.000333	0.00542	CbGeAlD
Sorafenib—RALBP1—pancreas—type 2 diabetes mellitus	0.000332	0.0054	CbGeAlD
Sorafenib—MKNK1—adipose tissue—type 2 diabetes mellitus	0.000329	0.00535	CbGeAlD
Sorafenib—PDGFRB—islet of Langerhans—type 2 diabetes mellitus	0.000328	0.00534	CbGeAlD
Sorafenib—RALBP1—cortex of kidney—type 2 diabetes mellitus	0.000325	0.00529	CbGeAlD
Sorafenib—FLT1—cardiovascular system—type 2 diabetes mellitus	0.000324	0.00528	CbGeAlD
Sorafenib—KDR—retina—type 2 diabetes mellitus	0.000324	0.00528	CbGeAlD
Sorafenib—RAF1—cardiovascular system—type 2 diabetes mellitus	0.000323	0.00525	CbGeAlD
Sorafenib—Vismodegib—CYP3A4—type 2 diabetes mellitus	0.000319	0.319	CrCbGaD
Sorafenib—FLT1—kidney—type 2 diabetes mellitus	0.000317	0.00517	CbGeAlD
Sorafenib—RAF1—kidney—type 2 diabetes mellitus	0.000316	0.00514	CbGeAlD
Sorafenib—FLT1—pancreas—type 2 diabetes mellitus	0.000315	0.00513	CbGeAlD
Sorafenib—RAF1—pancreas—type 2 diabetes mellitus	0.000313	0.0051	CbGeAlD
Sorafenib—TIE1—liver—type 2 diabetes mellitus	0.000312	0.00508	CbGeAlD
Sorafenib—FLT1—cortex of kidney—type 2 diabetes mellitus	0.000309	0.00503	CbGeAlD
Sorafenib—RAF1—cortex of kidney—type 2 diabetes mellitus	0.000307	0.005	CbGeAlD
Sorafenib—STK10—cardiovascular system—type 2 diabetes mellitus	0.000307	0.005	CbGeAlD
Sorafenib—EPHB6—cortex of kidney—type 2 diabetes mellitus	0.000306	0.00497	CbGeAlD
Sorafenib—KDR—nephron tubule—type 2 diabetes mellitus	0.000305	0.00497	CbGeAlD
Sorafenib—PDGFRA—cardiovascular system—type 2 diabetes mellitus	0.000304	0.00495	CbGeAlD
Sorafenib—RALBP1—adipose tissue—type 2 diabetes mellitus	0.000301	0.0049	CbGeAlD
Sorafenib—STK10—kidney—type 2 diabetes mellitus	0.0003	0.00489	CbGeAlD
Sorafenib—BRAF—liver—type 2 diabetes mellitus	0.000299	0.00487	CbGeAlD
Sorafenib—EPHX2—liver—type 2 diabetes mellitus	0.000286	0.00466	CbGeAlD
Sorafenib—FLT1—adipose tissue—type 2 diabetes mellitus	0.000286	0.00466	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—cortex of kidney—type 2 diabetes mellitus	0.000285	0.00464	CbGeAlD
Sorafenib—RAF1—adipose tissue—type 2 diabetes mellitus	0.000284	0.00463	CbGeAlD
Sorafenib—FLT3—liver—type 2 diabetes mellitus	0.000284	0.00462	CbGeAlD
Sorafenib—UGT1A1—kidney—type 2 diabetes mellitus	0.000284	0.00462	CbGeAlD
Sorafenib—EPHB6—adipose tissue—type 2 diabetes mellitus	0.000283	0.0046	CbGeAlD
Sorafenib—Vismodegib—ALB—type 2 diabetes mellitus	0.000278	0.278	CrCbGaD
Sorafenib—KDR—cardiovascular system—type 2 diabetes mellitus	0.000274	0.00446	CbGeAlD
Sorafenib—MAP2K5—cardiovascular system—type 2 diabetes mellitus	0.000274	0.00446	CbGeAlD
Sorafenib—STK10—adipose tissue—type 2 diabetes mellitus	0.000271	0.00441	CbGeAlD
Sorafenib—KIT—nephron tubule—type 2 diabetes mellitus	0.000271	0.0044	CbGeAlD
Sorafenib—KDR—kidney—type 2 diabetes mellitus	0.000268	0.00437	CbGeAlD
Sorafenib—PDGFRA—adipose tissue—type 2 diabetes mellitus	0.000268	0.00436	CbGeAlD
Sorafenib—CSF1R—cardiovascular system—type 2 diabetes mellitus	0.000268	0.00436	CbGeAlD
Sorafenib—UGT1A9—liver—type 2 diabetes mellitus	0.000262	0.00426	CbGeAlD
Sorafenib—MAP2K5—cortex of kidney—type 2 diabetes mellitus	0.000261	0.00425	CbGeAlD
Sorafenib—KDR—cortex of kidney—type 2 diabetes mellitus	0.000261	0.00425	CbGeAlD
Sorafenib—FLT4—liver—type 2 diabetes mellitus	0.000258	0.0042	CbGeAlD
Sorafenib—FGFR1—liver—type 2 diabetes mellitus	0.000255	0.00414	CbGeAlD
Sorafenib—KIT—cardiovascular system—type 2 diabetes mellitus	0.000243	0.00396	CbGeAlD
Sorafenib—MAP2K5—adipose tissue—type 2 diabetes mellitus	0.000242	0.00394	CbGeAlD
Sorafenib—KDR—adipose tissue—type 2 diabetes mellitus	0.000242	0.00394	CbGeAlD
Sorafenib—MAP3K7—liver—type 2 diabetes mellitus	0.000241	0.00392	CbGeAlD
Sorafenib—KIT—kidney—type 2 diabetes mellitus	0.000238	0.00387	CbGeAlD
Sorafenib—PDGFRB—cardiovascular system—type 2 diabetes mellitus	0.000237	0.00386	CbGeAlD
Sorafenib—KIT—pancreas—type 2 diabetes mellitus	0.000236	0.00384	CbGeAlD
Sorafenib—CSF1R—adipose tissue—type 2 diabetes mellitus	0.000236	0.00384	CbGeAlD
Sorafenib—MKNK2—liver—type 2 diabetes mellitus	0.000234	0.0038	CbGeAlD
Sorafenib—PDGFRB—kidney—type 2 diabetes mellitus	0.000232	0.00378	CbGeAlD
Sorafenib—KIT—cortex of kidney—type 2 diabetes mellitus	0.000232	0.00377	CbGeAlD
Sorafenib—PDGFRB—pancreas—type 2 diabetes mellitus	0.000231	0.00376	CbGeAlD
Sorafenib—MKNK1—liver—type 2 diabetes mellitus	0.000231	0.00375	CbGeAlD
Sorafenib—PDGFRB—cortex of kidney—type 2 diabetes mellitus	0.000226	0.00368	CbGeAlD
Sorafenib—CYP3A7—liver—type 2 diabetes mellitus	0.000218	0.00354	CbGeAlD
Sorafenib—KIT—adipose tissue—type 2 diabetes mellitus	0.000214	0.00349	CbGeAlD
Sorafenib—RALBP1—liver—type 2 diabetes mellitus	0.000211	0.00343	CbGeAlD
Sorafenib—ABCC4—nephron tubule—type 2 diabetes mellitus	0.00021	0.00343	CbGeAlD
Sorafenib—PDGFRB—adipose tissue—type 2 diabetes mellitus	0.000209	0.00341	CbGeAlD
Sorafenib—ABCC2—nephron tubule—type 2 diabetes mellitus	0.000204	0.00332	CbGeAlD
Sorafenib—FLT1—liver—type 2 diabetes mellitus	0.000201	0.00327	CbGeAlD
Sorafenib—RAF1—liver—type 2 diabetes mellitus	0.000199	0.00325	CbGeAlD
Sorafenib—STK10—liver—type 2 diabetes mellitus	0.00019	0.00309	CbGeAlD
Sorafenib—PDGFRA—liver—type 2 diabetes mellitus	0.000188	0.00306	CbGeAlD
Sorafenib—HTR2B—cardiovascular system—type 2 diabetes mellitus	0.000188	0.00306	CbGeAlD
Sorafenib—CYP3A7-CYP3A51P—liver—type 2 diabetes mellitus	0.000185	0.00301	CbGeAlD
Sorafenib—ABCC4—kidney—type 2 diabetes mellitus	0.000185	0.00301	CbGeAlD
Sorafenib—ABCC4—pancreas—type 2 diabetes mellitus	0.000184	0.00299	CbGeAlD
Sorafenib—ABCC4—cortex of kidney—type 2 diabetes mellitus	0.00018	0.00293	CbGeAlD
Sorafenib—UGT1A1—liver—type 2 diabetes mellitus	0.000179	0.00292	CbGeAlD
Sorafenib—HTR2B—cortex of kidney—type 2 diabetes mellitus	0.000179	0.00292	CbGeAlD
Sorafenib—ABCC2—kidney—type 2 diabetes mellitus	0.000179	0.00291	CbGeAlD
Sorafenib—ABCC2—cortex of kidney—type 2 diabetes mellitus	0.000174	0.00284	CbGeAlD
Sorafenib—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000171	0.00279	CbGeAlD
Sorafenib—KDR—liver—type 2 diabetes mellitus	0.00017	0.00276	CbGeAlD
Sorafenib—MAP2K5—liver—type 2 diabetes mellitus	0.00017	0.00276	CbGeAlD
Sorafenib—ABCC4—adipose tissue—type 2 diabetes mellitus	0.000167	0.00271	CbGeAlD
Sorafenib—HTR2B—adipose tissue—type 2 diabetes mellitus	0.000166	0.0027	CbGeAlD
Sorafenib—CSF1R—liver—type 2 diabetes mellitus	0.000166	0.00269	CbGeAlD
Sorafenib—KIT—liver—type 2 diabetes mellitus	0.00015	0.00245	CbGeAlD
Sorafenib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000149	0.00242	CbGeAlD
Sorafenib—PDGFRB—liver—type 2 diabetes mellitus	0.000147	0.00239	CbGeAlD
Sorafenib—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000138	0.00224	CbGeAlD
Sorafenib—CYP2B6—nephron tubule—type 2 diabetes mellitus	0.000137	0.00223	CbGeAlD
Sorafenib—CYP2C8—kidney—type 2 diabetes mellitus	0.000134	0.00219	CbGeAlD
Sorafenib—CYP2B6—cardiovascular system—type 2 diabetes mellitus	0.000123	0.002	CbGeAlD
Sorafenib—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.000122	0.00198	CbGeAlD
Sorafenib—CYP3A5—kidney—type 2 diabetes mellitus	0.000121	0.00197	CbGeAlD
Sorafenib—CYP2B6—kidney—type 2 diabetes mellitus	0.00012	0.00196	CbGeAlD
Sorafenib—CYP3A5—pancreas—type 2 diabetes mellitus	0.00012	0.00196	CbGeAlD
Sorafenib—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.000118	0.00192	CbGeAlD
Sorafenib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000118	0.00191	CbGeAlD
Sorafenib—ABCC4—liver—type 2 diabetes mellitus	0.000117	0.0019	CbGeAlD
Sorafenib—ABCC2—liver—type 2 diabetes mellitus	0.000113	0.00184	CbGeAlD
Sorafenib—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000109	0.00178	CbGeAlD
Sorafenib—CYP2C19—liver—type 2 diabetes mellitus	9.72e-05	0.00158	CbGeAlD
Sorafenib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	9.1e-05	0.00148	CbGeAlD
Sorafenib—CYP3A4—kidney—type 2 diabetes mellitus	9.09e-05	0.00148	CbGeAlD
Sorafenib—CYP2D6—kidney—type 2 diabetes mellitus	8.95e-05	0.00146	CbGeAlD
Sorafenib—CYP2C8—liver—type 2 diabetes mellitus	8.49e-05	0.00138	CbGeAlD
Sorafenib—ABCG2—liver—type 2 diabetes mellitus	8.25e-05	0.00134	CbGeAlD
Sorafenib—CYP1A2—liver—type 2 diabetes mellitus	7.94e-05	0.00129	CbGeAlD
Sorafenib—ABCB1—retina—type 2 diabetes mellitus	7.78e-05	0.00127	CbGeAlD
Sorafenib—CYP3A5—liver—type 2 diabetes mellitus	7.66e-05	0.00125	CbGeAlD
Sorafenib—CYP2B6—liver—type 2 diabetes mellitus	7.61e-05	0.00124	CbGeAlD
Sorafenib—CYP2C9—liver—type 2 diabetes mellitus	7.54e-05	0.00123	CbGeAlD
Sorafenib—Skin disorder—Valsartan—type 2 diabetes mellitus	7.5e-05	0.000563	CcSEcCtD
Sorafenib—Dysgeusia—Losartan—type 2 diabetes mellitus	7.49e-05	0.000562	CcSEcCtD
Sorafenib—Dyspnoea—Gliclazide—type 2 diabetes mellitus	7.49e-05	0.000562	CcSEcCtD
Sorafenib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	7.48e-05	0.000562	CcSEcCtD
Sorafenib—Dizziness—Sitagliptin—type 2 diabetes mellitus	7.48e-05	0.000561	CcSEcCtD
Sorafenib—Hypertension—Metformin—type 2 diabetes mellitus	7.44e-05	0.000558	CcSEcCtD
Sorafenib—Urticaria—Glyburide—type 2 diabetes mellitus	7.43e-05	0.000558	CcSEcCtD
Sorafenib—Angioedema—Irbesartan—type 2 diabetes mellitus	7.43e-05	0.000558	CcSEcCtD
Sorafenib—Skin disorder—Orlistat—type 2 diabetes mellitus	7.41e-05	0.000556	CcSEcCtD
Sorafenib—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	7.4e-05	0.000556	CcSEcCtD
Sorafenib—Abdominal pain—Glyburide—type 2 diabetes mellitus	7.4e-05	0.000555	CcSEcCtD
Sorafenib—Dyspepsia—Gliclazide—type 2 diabetes mellitus	7.4e-05	0.000555	CcSEcCtD
Sorafenib—Anorexia—Valsartan—type 2 diabetes mellitus	7.36e-05	0.000552	CcSEcCtD
Sorafenib—Muscle spasms—Losartan—type 2 diabetes mellitus	7.35e-05	0.000552	CcSEcCtD
Sorafenib—Asthenia—Bromocriptine—type 2 diabetes mellitus	7.34e-05	0.000551	CcSEcCtD
Sorafenib—Myalgia—Metformin—type 2 diabetes mellitus	7.33e-05	0.000551	CcSEcCtD
Sorafenib—ABCB1—nephron tubule—type 2 diabetes mellitus	7.32e-05	0.00119	CbGeAlD
Sorafenib—Headache—Pioglitazone—type 2 diabetes mellitus	7.3e-05	0.000548	CcSEcCtD
Sorafenib—Syncope—Irbesartan—type 2 diabetes mellitus	7.29e-05	0.000547	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	7.28e-05	0.000547	CcSEcCtD
Sorafenib—Leukopenia—Irbesartan—type 2 diabetes mellitus	7.28e-05	0.000546	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	7.25e-05	0.000545	CcSEcCtD
Sorafenib—Fatigue—Gliclazide—type 2 diabetes mellitus	7.24e-05	0.000544	CcSEcCtD
Sorafenib—Nausea—Glipizide—type 2 diabetes mellitus	7.22e-05	0.000542	CcSEcCtD
Sorafenib—Vomiting—Glimepiride—type 2 diabetes mellitus	7.21e-05	0.000542	CcSEcCtD
Sorafenib—Vomiting—Sitagliptin—type 2 diabetes mellitus	7.19e-05	0.00054	CcSEcCtD
Sorafenib—Constipation—Gliclazide—type 2 diabetes mellitus	7.19e-05	0.000539	CcSEcCtD
Sorafenib—Pain—Gliclazide—type 2 diabetes mellitus	7.19e-05	0.000539	CcSEcCtD
Sorafenib—Rash—Glimepiride—type 2 diabetes mellitus	7.15e-05	0.000537	CcSEcCtD
Sorafenib—Dermatitis—Glimepiride—type 2 diabetes mellitus	7.15e-05	0.000537	CcSEcCtD
Sorafenib—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	7.14e-05	0.000536	CcSEcCtD
Sorafenib—Rash—Sitagliptin—type 2 diabetes mellitus	7.13e-05	0.000535	CcSEcCtD
Sorafenib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	7.12e-05	0.000535	CcSEcCtD
Sorafenib—Erythema multiforme—Ramipril—type 2 diabetes mellitus	7.12e-05	0.000535	CcSEcCtD
Sorafenib—Headache—Glimepiride—type 2 diabetes mellitus	7.11e-05	0.000534	CcSEcCtD
Sorafenib—Cough—Irbesartan—type 2 diabetes mellitus	7.09e-05	0.000532	CcSEcCtD
Sorafenib—Headache—Sitagliptin—type 2 diabetes mellitus	7.09e-05	0.000532	CcSEcCtD
Sorafenib—Anaemia—Losartan—type 2 diabetes mellitus	7.07e-05	0.000531	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	7.03e-05	0.000528	CcSEcCtD
Sorafenib—Tinnitus—Ramipril—type 2 diabetes mellitus	7.03e-05	0.000527	CcSEcCtD
Sorafenib—Hypertension—Irbesartan—type 2 diabetes mellitus	7.02e-05	0.000527	CcSEcCtD
Sorafenib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	7e-05	0.000526	CcSEcCtD
Sorafenib—Flushing—Ramipril—type 2 diabetes mellitus	6.99e-05	0.000525	CcSEcCtD
Sorafenib—Angioedema—Losartan—type 2 diabetes mellitus	6.99e-05	0.000525	CcSEcCtD
Sorafenib—Infection—Metformin—type 2 diabetes mellitus	6.98e-05	0.000524	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	6.95e-05	0.000522	CcSEcCtD
Sorafenib—Myalgia—Irbesartan—type 2 diabetes mellitus	6.92e-05	0.00052	CcSEcCtD
Sorafenib—Arthralgia—Irbesartan—type 2 diabetes mellitus	6.92e-05	0.00052	CcSEcCtD
Sorafenib—Shock—Metformin—type 2 diabetes mellitus	6.92e-05	0.000519	CcSEcCtD
Sorafenib—Hypersensitivity—Glyburide—type 2 diabetes mellitus	6.89e-05	0.000518	CcSEcCtD
Sorafenib—Nervous system disorder—Metformin—type 2 diabetes mellitus	6.89e-05	0.000518	CcSEcCtD
Sorafenib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	6.88e-05	0.000517	CcSEcCtD
Sorafenib—Dyspnoea—Valsartan—type 2 diabetes mellitus	6.88e-05	0.000517	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	6.87e-05	0.000516	CcSEcCtD
Sorafenib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	6.87e-05	0.000516	CcSEcCtD
Sorafenib—Syncope—Losartan—type 2 diabetes mellitus	6.86e-05	0.000515	CcSEcCtD
Sorafenib—Leukopenia—Losartan—type 2 diabetes mellitus	6.85e-05	0.000514	CcSEcCtD
Sorafenib—Skin disorder—Metformin—type 2 diabetes mellitus	6.83e-05	0.000513	CcSEcCtD
Sorafenib—Immune system disorder—Ramipril—type 2 diabetes mellitus	6.81e-05	0.000511	CcSEcCtD
Sorafenib—Dyspepsia—Valsartan—type 2 diabetes mellitus	6.8e-05	0.00051	CcSEcCtD
Sorafenib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	6.79e-05	0.00051	CcSEcCtD
Sorafenib—Dizziness—Bromocriptine—type 2 diabetes mellitus	6.77e-05	0.000508	CcSEcCtD
Sorafenib—Dry mouth—Irbesartan—type 2 diabetes mellitus	6.77e-05	0.000508	CcSEcCtD
Sorafenib—Nausea—Glimepiride—type 2 diabetes mellitus	6.74e-05	0.000506	CcSEcCtD
Sorafenib—Arrhythmia—Ramipril—type 2 diabetes mellitus	6.73e-05	0.000505	CcSEcCtD
Sorafenib—Loss of consciousness—Losartan—type 2 diabetes mellitus	6.72e-05	0.000505	CcSEcCtD
Sorafenib—Nausea—Sitagliptin—type 2 diabetes mellitus	6.72e-05	0.000504	CcSEcCtD
Sorafenib—Dyspepsia—Orlistat—type 2 diabetes mellitus	6.71e-05	0.000504	CcSEcCtD
Sorafenib—Asthenia—Glyburide—type 2 diabetes mellitus	6.71e-05	0.000504	CcSEcCtD
Sorafenib—Decreased appetite—Valsartan—type 2 diabetes mellitus	6.71e-05	0.000504	CcSEcCtD
Sorafenib—Anorexia—Metformin—type 2 diabetes mellitus	6.7e-05	0.000503	CcSEcCtD
Sorafenib—Cough—Losartan—type 2 diabetes mellitus	6.68e-05	0.000501	CcSEcCtD
Sorafenib—Urticaria—Gliclazide—type 2 diabetes mellitus	6.67e-05	0.000501	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	6.66e-05	0.0005	CcSEcCtD
Sorafenib—Alopecia—Ramipril—type 2 diabetes mellitus	6.66e-05	0.0005	CcSEcCtD
Sorafenib—Fatigue—Valsartan—type 2 diabetes mellitus	6.66e-05	0.0005	CcSEcCtD
Sorafenib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	6.64e-05	0.000499	CcSEcCtD
Sorafenib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	6.64e-05	0.000499	CcSEcCtD
Sorafenib—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	6.63e-05	0.000498	CcSEcCtD
Sorafenib—Decreased appetite—Orlistat—type 2 diabetes mellitus	6.63e-05	0.000498	CcSEcCtD
Sorafenib—Pruritus—Glyburide—type 2 diabetes mellitus	6.62e-05	0.000497	CcSEcCtD
Sorafenib—Mental disorder—Ramipril—type 2 diabetes mellitus	6.6e-05	0.000496	CcSEcCtD
Sorafenib—Constipation—Valsartan—type 2 diabetes mellitus	6.6e-05	0.000496	CcSEcCtD
Sorafenib—Infection—Irbesartan—type 2 diabetes mellitus	6.59e-05	0.000495	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	6.59e-05	0.000494	CcSEcCtD
Sorafenib—ABCB1—cardiovascular system—type 2 diabetes mellitus	6.58e-05	0.00107	CbGeAlD
Sorafenib—Fatigue—Orlistat—type 2 diabetes mellitus	6.58e-05	0.000494	CcSEcCtD
Sorafenib—Malnutrition—Ramipril—type 2 diabetes mellitus	6.56e-05	0.000492	CcSEcCtD
Sorafenib—Erythema—Ramipril—type 2 diabetes mellitus	6.56e-05	0.000492	CcSEcCtD
Sorafenib—Shock—Irbesartan—type 2 diabetes mellitus	6.53e-05	0.00049	CcSEcCtD
Sorafenib—Pain—Orlistat—type 2 diabetes mellitus	6.52e-05	0.00049	CcSEcCtD
Sorafenib—Myalgia—Losartan—type 2 diabetes mellitus	6.51e-05	0.000489	CcSEcCtD
Sorafenib—Arthralgia—Losartan—type 2 diabetes mellitus	6.51e-05	0.000489	CcSEcCtD
Sorafenib—Vomiting—Bromocriptine—type 2 diabetes mellitus	6.51e-05	0.000489	CcSEcCtD
Sorafenib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	6.51e-05	0.000488	CcSEcCtD
Sorafenib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	6.5e-05	0.000488	CcSEcCtD
Sorafenib—Rash—Bromocriptine—type 2 diabetes mellitus	6.45e-05	0.000484	CcSEcCtD
Sorafenib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	6.45e-05	0.000484	CcSEcCtD
Sorafenib—Skin disorder—Irbesartan—type 2 diabetes mellitus	6.44e-05	0.000484	CcSEcCtD
Sorafenib—ABCB1—kidney—type 2 diabetes mellitus	6.44e-05	0.00105	CbGeAlD
Sorafenib—Dysgeusia—Ramipril—type 2 diabetes mellitus	6.42e-05	0.000482	CcSEcCtD
Sorafenib—Headache—Bromocriptine—type 2 diabetes mellitus	6.41e-05	0.000481	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	6.4e-05	0.000481	CcSEcCtD
Sorafenib—Diarrhoea—Glyburide—type 2 diabetes mellitus	6.4e-05	0.000481	CcSEcCtD
Sorafenib—ABCB1—pancreas—type 2 diabetes mellitus	6.39e-05	0.00104	CbGeAlD
Sorafenib—Dry mouth—Losartan—type 2 diabetes mellitus	6.37e-05	0.000478	CcSEcCtD
Sorafenib—Anorexia—Irbesartan—type 2 diabetes mellitus	6.32e-05	0.000475	CcSEcCtD
Sorafenib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	6.31e-05	0.000474	CcSEcCtD
Sorafenib—Muscle spasms—Ramipril—type 2 diabetes mellitus	6.31e-05	0.000473	CcSEcCtD
Sorafenib—ABCB1—cortex of kidney—type 2 diabetes mellitus	6.27e-05	0.00102	CbGeAlD
Sorafenib—Dyspnoea—Metformin—type 2 diabetes mellitus	6.27e-05	0.00047	CcSEcCtD
Sorafenib—Anaphylactic shock—Losartan—type 2 diabetes mellitus	6.24e-05	0.000469	CcSEcCtD
Sorafenib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	6.24e-05	0.000468	CcSEcCtD
Sorafenib—Infection—Losartan—type 2 diabetes mellitus	6.2e-05	0.000466	CcSEcCtD
Sorafenib—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	6.19e-05	0.000465	CcSEcCtD
Sorafenib—Dyspepsia—Metformin—type 2 diabetes mellitus	6.19e-05	0.000465	CcSEcCtD
Sorafenib—Shock—Losartan—type 2 diabetes mellitus	6.14e-05	0.000461	CcSEcCtD
Sorafenib—Urticaria—Valsartan—type 2 diabetes mellitus	6.13e-05	0.00046	CcSEcCtD
Sorafenib—Nervous system disorder—Losartan—type 2 diabetes mellitus	6.12e-05	0.00046	CcSEcCtD
Sorafenib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	6.11e-05	0.000459	CcSEcCtD
Sorafenib—Decreased appetite—Metformin—type 2 diabetes mellitus	6.11e-05	0.000459	CcSEcCtD
Sorafenib—Abdominal pain—Valsartan—type 2 diabetes mellitus	6.1e-05	0.000458	CcSEcCtD
Sorafenib—Nausea—Bromocriptine—type 2 diabetes mellitus	6.08e-05	0.000456	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	6.07e-05	0.000456	CcSEcCtD
Sorafenib—Fatigue—Metformin—type 2 diabetes mellitus	6.06e-05	0.000455	CcSEcCtD
Sorafenib—Urticaria—Orlistat—type 2 diabetes mellitus	6.06e-05	0.000455	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	6.04e-05	0.000454	CcSEcCtD
Sorafenib—Abdominal pain—Orlistat—type 2 diabetes mellitus	6.03e-05	0.000453	CcSEcCtD
Sorafenib—Body temperature increased—Orlistat—type 2 diabetes mellitus	6.03e-05	0.000453	CcSEcCtD
Sorafenib—Asthenia—Gliclazide—type 2 diabetes mellitus	6.03e-05	0.000453	CcSEcCtD
Sorafenib—Constipation—Metformin—type 2 diabetes mellitus	6.01e-05	0.000451	CcSEcCtD
Sorafenib—Angioedema—Ramipril—type 2 diabetes mellitus	5.99e-05	0.00045	CcSEcCtD
Sorafenib—Anorexia—Losartan—type 2 diabetes mellitus	5.95e-05	0.000447	CcSEcCtD
Sorafenib—Vomiting—Glyburide—type 2 diabetes mellitus	5.95e-05	0.000447	CcSEcCtD
Sorafenib—Pruritus—Gliclazide—type 2 diabetes mellitus	5.94e-05	0.000446	CcSEcCtD
Sorafenib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	5.91e-05	0.000444	CcSEcCtD
Sorafenib—Rash—Glyburide—type 2 diabetes mellitus	5.9e-05	0.000443	CcSEcCtD
Sorafenib—Dermatitis—Glyburide—type 2 diabetes mellitus	5.89e-05	0.000442	CcSEcCtD
Sorafenib—Syncope—Ramipril—type 2 diabetes mellitus	5.88e-05	0.000442	CcSEcCtD
Sorafenib—Leukopenia—Ramipril—type 2 diabetes mellitus	5.87e-05	0.000441	CcSEcCtD
Sorafenib—Headache—Glyburide—type 2 diabetes mellitus	5.86e-05	0.00044	CcSEcCtD
Sorafenib—Dyspepsia—Irbesartan—type 2 diabetes mellitus	5.84e-05	0.000438	CcSEcCtD
Sorafenib—ABCB1—adipose tissue—type 2 diabetes mellitus	5.8e-05	0.000944	CbGeAlD
Sorafenib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	5.77e-05	0.000433	CcSEcCtD
Sorafenib—Loss of consciousness—Ramipril—type 2 diabetes mellitus	5.77e-05	0.000433	CcSEcCtD
Sorafenib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	5.75e-05	0.000432	CcSEcCtD
Sorafenib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	5.75e-05	0.000432	CcSEcCtD
Sorafenib—CYP3A4—liver—type 2 diabetes mellitus	5.75e-05	0.000936	CbGeAlD
Sorafenib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	5.73e-05	0.00043	CcSEcCtD
Sorafenib—Cough—Ramipril—type 2 diabetes mellitus	5.72e-05	0.00043	CcSEcCtD
Sorafenib—Fatigue—Irbesartan—type 2 diabetes mellitus	5.72e-05	0.000429	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	5.69e-05	0.000427	CcSEcCtD
Sorafenib—Hypersensitivity—Valsartan—type 2 diabetes mellitus	5.69e-05	0.000427	CcSEcCtD
Sorafenib—Pain—Irbesartan—type 2 diabetes mellitus	5.67e-05	0.000426	CcSEcCtD
Sorafenib—Constipation—Irbesartan—type 2 diabetes mellitus	5.67e-05	0.000426	CcSEcCtD
Sorafenib—CYP2D6—liver—type 2 diabetes mellitus	5.66e-05	0.000921	CbGeAlD
Sorafenib—Hypersensitivity—Orlistat—type 2 diabetes mellitus	5.62e-05	0.000422	CcSEcCtD
Sorafenib—Urticaria—Metformin—type 2 diabetes mellitus	5.58e-05	0.000419	CcSEcCtD
Sorafenib—Arthralgia—Ramipril—type 2 diabetes mellitus	5.58e-05	0.000419	CcSEcCtD
Sorafenib—Myalgia—Ramipril—type 2 diabetes mellitus	5.58e-05	0.000419	CcSEcCtD
Sorafenib—Dyspnoea—Losartan—type 2 diabetes mellitus	5.57e-05	0.000418	CcSEcCtD
Sorafenib—Nausea—Glyburide—type 2 diabetes mellitus	5.56e-05	0.000417	CcSEcCtD
Sorafenib—Abdominal pain—Metformin—type 2 diabetes mellitus	5.56e-05	0.000417	CcSEcCtD
Sorafenib—Dizziness—Gliclazide—type 2 diabetes mellitus	5.56e-05	0.000417	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	5.55e-05	0.000416	CcSEcCtD
Sorafenib—Asthenia—Valsartan—type 2 diabetes mellitus	5.54e-05	0.000416	CcSEcCtD
Sorafenib—Dyspepsia—Losartan—type 2 diabetes mellitus	5.5e-05	0.000413	CcSEcCtD
Sorafenib—Asthenia—Orlistat—type 2 diabetes mellitus	5.47e-05	0.000411	CcSEcCtD
Sorafenib—Pruritus—Valsartan—type 2 diabetes mellitus	5.46e-05	0.00041	CcSEcCtD
Sorafenib—Dry mouth—Ramipril—type 2 diabetes mellitus	5.46e-05	0.00041	CcSEcCtD
Sorafenib—Decreased appetite—Losartan—type 2 diabetes mellitus	5.43e-05	0.000407	CcSEcCtD
Sorafenib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	5.42e-05	0.000407	CcSEcCtD
Sorafenib—Pruritus—Orlistat—type 2 diabetes mellitus	5.4e-05	0.000405	CcSEcCtD
Sorafenib—Fatigue—Losartan—type 2 diabetes mellitus	5.38e-05	0.000404	CcSEcCtD
Sorafenib—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	5.35e-05	0.000402	CcSEcCtD
Sorafenib—Vomiting—Gliclazide—type 2 diabetes mellitus	5.34e-05	0.000401	CcSEcCtD
Sorafenib—Pain—Losartan—type 2 diabetes mellitus	5.34e-05	0.000401	CcSEcCtD
Sorafenib—Constipation—Losartan—type 2 diabetes mellitus	5.34e-05	0.000401	CcSEcCtD
Sorafenib—Rash—Gliclazide—type 2 diabetes mellitus	5.3e-05	0.000398	CcSEcCtD
Sorafenib—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.29e-05	0.000397	CcSEcCtD
Sorafenib—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.28e-05	0.000397	CcSEcCtD
Sorafenib—Urticaria—Irbesartan—type 2 diabetes mellitus	5.27e-05	0.000396	CcSEcCtD
Sorafenib—Shock—Ramipril—type 2 diabetes mellitus	5.27e-05	0.000395	CcSEcCtD
Sorafenib—Headache—Gliclazide—type 2 diabetes mellitus	5.26e-05	0.000395	CcSEcCtD
Sorafenib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	5.25e-05	0.000394	CcSEcCtD
Sorafenib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	5.24e-05	0.000394	CcSEcCtD
Sorafenib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	5.24e-05	0.000394	CcSEcCtD
Sorafenib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	5.24e-05	0.000393	CcSEcCtD
Sorafenib—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.22e-05	0.000392	CcSEcCtD
Sorafenib—Skin disorder—Ramipril—type 2 diabetes mellitus	5.2e-05	0.00039	CcSEcCtD
Sorafenib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	5.11e-05	0.000383	CcSEcCtD
Sorafenib—Dizziness—Valsartan—type 2 diabetes mellitus	5.1e-05	0.000383	CcSEcCtD
Sorafenib—Anorexia—Ramipril—type 2 diabetes mellitus	5.1e-05	0.000383	CcSEcCtD
Sorafenib—Dizziness—Orlistat—type 2 diabetes mellitus	5.04e-05	0.000379	CcSEcCtD
Sorafenib—Asthenia—Metformin—type 2 diabetes mellitus	5.04e-05	0.000379	CcSEcCtD
Sorafenib—Nausea—Gliclazide—type 2 diabetes mellitus	4.99e-05	0.000375	CcSEcCtD
Sorafenib—Pruritus—Metformin—type 2 diabetes mellitus	4.97e-05	0.000373	CcSEcCtD
Sorafenib—Urticaria—Losartan—type 2 diabetes mellitus	4.96e-05	0.000372	CcSEcCtD
Sorafenib—Abdominal pain—Losartan—type 2 diabetes mellitus	4.94e-05	0.000371	CcSEcCtD
Sorafenib—Body temperature increased—Losartan—type 2 diabetes mellitus	4.94e-05	0.000371	CcSEcCtD
Sorafenib—Vomiting—Valsartan—type 2 diabetes mellitus	4.91e-05	0.000368	CcSEcCtD
Sorafenib—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	4.89e-05	0.000367	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.88e-05	0.000366	CcSEcCtD
Sorafenib—Rash—Valsartan—type 2 diabetes mellitus	4.87e-05	0.000365	CcSEcCtD
Sorafenib—Dermatitis—Valsartan—type 2 diabetes mellitus	4.86e-05	0.000365	CcSEcCtD
Sorafenib—Vomiting—Orlistat—type 2 diabetes mellitus	4.85e-05	0.000364	CcSEcCtD
Sorafenib—Headache—Valsartan—type 2 diabetes mellitus	4.84e-05	0.000363	CcSEcCtD
Sorafenib—Diarrhoea—Metformin—type 2 diabetes mellitus	4.81e-05	0.000361	CcSEcCtD
Sorafenib—Rash—Orlistat—type 2 diabetes mellitus	4.81e-05	0.000361	CcSEcCtD
Sorafenib—Dermatitis—Orlistat—type 2 diabetes mellitus	4.81e-05	0.000361	CcSEcCtD
Sorafenib—Headache—Orlistat—type 2 diabetes mellitus	4.78e-05	0.000359	CcSEcCtD
Sorafenib—Dyspnoea—Ramipril—type 2 diabetes mellitus	4.77e-05	0.000358	CcSEcCtD
Sorafenib—Asthenia—Irbesartan—type 2 diabetes mellitus	4.76e-05	0.000357	CcSEcCtD
Sorafenib—Dyspepsia—Ramipril—type 2 diabetes mellitus	4.71e-05	0.000354	CcSEcCtD
Sorafenib—Pruritus—Irbesartan—type 2 diabetes mellitus	4.69e-05	0.000352	CcSEcCtD
Sorafenib—Decreased appetite—Ramipril—type 2 diabetes mellitus	4.65e-05	0.000349	CcSEcCtD
Sorafenib—Dizziness—Metformin—type 2 diabetes mellitus	4.65e-05	0.000349	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.62e-05	0.000347	CcSEcCtD
Sorafenib—Fatigue—Ramipril—type 2 diabetes mellitus	4.62e-05	0.000346	CcSEcCtD
Sorafenib—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.6e-05	0.000345	CcSEcCtD
Sorafenib—Nausea—Valsartan—type 2 diabetes mellitus	4.59e-05	0.000344	CcSEcCtD
Sorafenib—Constipation—Ramipril—type 2 diabetes mellitus	4.58e-05	0.000344	CcSEcCtD
Sorafenib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.54e-05	0.000341	CcSEcCtD
Sorafenib—Nausea—Orlistat—type 2 diabetes mellitus	4.53e-05	0.00034	CcSEcCtD
Sorafenib—Asthenia—Losartan—type 2 diabetes mellitus	4.48e-05	0.000336	CcSEcCtD
Sorafenib—Vomiting—Metformin—type 2 diabetes mellitus	4.47e-05	0.000336	CcSEcCtD
Sorafenib—Rash—Metformin—type 2 diabetes mellitus	4.43e-05	0.000333	CcSEcCtD
Sorafenib—Dermatitis—Metformin—type 2 diabetes mellitus	4.43e-05	0.000332	CcSEcCtD
Sorafenib—Pruritus—Losartan—type 2 diabetes mellitus	4.42e-05	0.000332	CcSEcCtD
Sorafenib—Headache—Metformin—type 2 diabetes mellitus	4.4e-05	0.000331	CcSEcCtD
Sorafenib—Dizziness—Irbesartan—type 2 diabetes mellitus	4.39e-05	0.000329	CcSEcCtD
Sorafenib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	4.38e-05	0.000329	CcSEcCtD
Sorafenib—Diarrhoea—Losartan—type 2 diabetes mellitus	4.27e-05	0.000321	CcSEcCtD
Sorafenib—Urticaria—Ramipril—type 2 diabetes mellitus	4.25e-05	0.000319	CcSEcCtD
Sorafenib—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.23e-05	0.000318	CcSEcCtD
Sorafenib—Abdominal pain—Ramipril—type 2 diabetes mellitus	4.23e-05	0.000318	CcSEcCtD
Sorafenib—Vomiting—Irbesartan—type 2 diabetes mellitus	4.22e-05	0.000317	CcSEcCtD
Sorafenib—Rash—Irbesartan—type 2 diabetes mellitus	4.18e-05	0.000314	CcSEcCtD
Sorafenib—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.18e-05	0.000314	CcSEcCtD
Sorafenib—Nausea—Metformin—type 2 diabetes mellitus	4.18e-05	0.000313	CcSEcCtD
Sorafenib—Headache—Irbesartan—type 2 diabetes mellitus	4.16e-05	0.000312	CcSEcCtD
Sorafenib—Dizziness—Losartan—type 2 diabetes mellitus	4.13e-05	0.00031	CcSEcCtD
Sorafenib—ABCB1—liver—type 2 diabetes mellitus	4.07e-05	0.000662	CbGeAlD
Sorafenib—Vomiting—Losartan—type 2 diabetes mellitus	3.97e-05	0.000298	CcSEcCtD
Sorafenib—Hypersensitivity—Ramipril—type 2 diabetes mellitus	3.94e-05	0.000296	CcSEcCtD
Sorafenib—Nausea—Irbesartan—type 2 diabetes mellitus	3.94e-05	0.000296	CcSEcCtD
Sorafenib—Rash—Losartan—type 2 diabetes mellitus	3.94e-05	0.000296	CcSEcCtD
Sorafenib—Dermatitis—Losartan—type 2 diabetes mellitus	3.93e-05	0.000295	CcSEcCtD
Sorafenib—Headache—Losartan—type 2 diabetes mellitus	3.91e-05	0.000294	CcSEcCtD
Sorafenib—Asthenia—Ramipril—type 2 diabetes mellitus	3.84e-05	0.000288	CcSEcCtD
Sorafenib—Pruritus—Ramipril—type 2 diabetes mellitus	3.79e-05	0.000284	CcSEcCtD
Sorafenib—Nausea—Losartan—type 2 diabetes mellitus	3.71e-05	0.000278	CcSEcCtD
Sorafenib—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.66e-05	0.000275	CcSEcCtD
Sorafenib—Dizziness—Ramipril—type 2 diabetes mellitus	3.54e-05	0.000266	CcSEcCtD
Sorafenib—Vomiting—Ramipril—type 2 diabetes mellitus	3.4e-05	0.000256	CcSEcCtD
Sorafenib—Rash—Ramipril—type 2 diabetes mellitus	3.38e-05	0.000253	CcSEcCtD
Sorafenib—Dermatitis—Ramipril—type 2 diabetes mellitus	3.37e-05	0.000253	CcSEcCtD
Sorafenib—Headache—Ramipril—type 2 diabetes mellitus	3.35e-05	0.000252	CcSEcCtD
Sorafenib—Nausea—Ramipril—type 2 diabetes mellitus	3.18e-05	0.000239	CcSEcCtD
Sorafenib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	8.69e-07	7.24e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ADCY5—type 2 diabetes mellitus	8.68e-07	7.23e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.68e-07	7.23e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.67e-07	7.22e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	8.66e-07	7.21e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—GPX1—type 2 diabetes mellitus	8.65e-07	7.21e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.65e-07	7.2e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.59e-07	7.15e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PPARG—type 2 diabetes mellitus	8.57e-07	7.14e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—type 2 diabetes mellitus	8.56e-07	7.13e-06	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—type 2 diabetes mellitus	8.56e-07	7.13e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	8.54e-07	7.12e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—type 2 diabetes mellitus	8.54e-07	7.12e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—type 2 diabetes mellitus	8.54e-07	7.11e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	8.53e-07	7.11e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AGT—type 2 diabetes mellitus	8.5e-07	7.08e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	8.48e-07	7.06e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	8.47e-07	7.06e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	8.45e-07	7.04e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	8.43e-07	7.02e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CD36—type 2 diabetes mellitus	8.43e-07	7.02e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—INS—type 2 diabetes mellitus	8.41e-07	7e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.39e-07	6.99e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.39e-07	6.99e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	8.38e-07	6.98e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—type 2 diabetes mellitus	8.36e-07	6.97e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CALM1—type 2 diabetes mellitus	8.36e-07	6.96e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—type 2 diabetes mellitus	8.34e-07	6.94e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOE—type 2 diabetes mellitus	8.33e-07	6.94e-06	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—type 2 diabetes mellitus	8.32e-07	6.93e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPP2CA—type 2 diabetes mellitus	8.32e-07	6.93e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.32e-07	6.93e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.32e-07	6.93e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	8.31e-07	6.92e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.28e-07	6.89e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	8.24e-07	6.86e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—APOA1—type 2 diabetes mellitus	8.23e-07	6.86e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	8.23e-07	6.85e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.22e-07	6.85e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.22e-07	6.85e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	8.22e-07	6.84e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.19e-07	6.82e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.18e-07	6.82e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	8.16e-07	6.8e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—type 2 diabetes mellitus	8.15e-07	6.79e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—type 2 diabetes mellitus	8.13e-07	6.77e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	8.12e-07	6.77e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	8.09e-07	6.74e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.03e-07	6.69e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SRC—type 2 diabetes mellitus	8e-07	6.66e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	7.99e-07	6.65e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—type 2 diabetes mellitus	7.99e-07	6.65e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	7.96e-07	6.63e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.96e-07	6.63e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.94e-07	6.61e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	7.92e-07	6.6e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—type 2 diabetes mellitus	7.9e-07	6.58e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	7.89e-07	6.57e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—type 2 diabetes mellitus	7.88e-07	6.56e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	7.84e-07	6.53e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	7.84e-07	6.53e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	7.84e-07	6.53e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARA—type 2 diabetes mellitus	7.83e-07	6.53e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RELA—type 2 diabetes mellitus	7.83e-07	6.52e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.8e-07	6.5e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	7.79e-07	6.49e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.79e-07	6.49e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.78e-07	6.48e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	7.75e-07	6.46e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.73e-07	6.44e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.72e-07	6.43e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—type 2 diabetes mellitus	7.71e-07	6.42e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—type 2 diabetes mellitus	7.7e-07	6.41e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	7.7e-07	6.41e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—type 2 diabetes mellitus	7.69e-07	6.41e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	7.68e-07	6.4e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	7.65e-07	6.38e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.65e-07	6.37e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	7.65e-07	6.37e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SRC—type 2 diabetes mellitus	7.63e-07	6.36e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	7.63e-07	6.35e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	7.59e-07	6.32e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.59e-07	6.32e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	7.59e-07	6.32e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AGT—type 2 diabetes mellitus	7.59e-07	6.32e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	7.56e-07	6.29e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	7.53e-07	6.27e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.52e-07	6.26e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	7.5e-07	6.25e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	7.46e-07	6.22e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CALM1—type 2 diabetes mellitus	7.46e-07	6.21e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	7.46e-07	6.21e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOE—type 2 diabetes mellitus	7.43e-07	6.19e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.43e-07	6.19e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—type 2 diabetes mellitus	7.43e-07	6.19e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	7.41e-07	6.17e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—type 2 diabetes mellitus	7.37e-07	6.14e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3R1—type 2 diabetes mellitus	7.37e-07	6.14e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—APOA1—type 2 diabetes mellitus	7.35e-07	6.12e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	7.35e-07	6.12e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	7.28e-07	6.07e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	7.28e-07	6.07e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	7.26e-07	6.04e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—type 2 diabetes mellitus	7.26e-07	6.04e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	7.24e-07	6.03e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	7.21e-07	6e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	7.2e-07	6e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	7.2e-07	6e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	7.17e-07	5.98e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	7.17e-07	5.97e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.15e-07	5.96e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	7.14e-07	5.95e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SRC—type 2 diabetes mellitus	7.13e-07	5.94e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	7.13e-07	5.94e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—INS—type 2 diabetes mellitus	7.12e-07	5.93e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—type 2 diabetes mellitus	7.1e-07	5.91e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	7.09e-07	5.91e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	7.09e-07	5.91e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.06e-07	5.88e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	7.04e-07	5.86e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	7.02e-07	5.85e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.01e-07	5.84e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—type 2 diabetes mellitus	7.01e-07	5.84e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	6.98e-07	5.81e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.94e-07	5.78e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—type 2 diabetes mellitus	6.94e-07	5.78e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	6.92e-07	5.76e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	6.91e-07	5.76e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	6.86e-07	5.72e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—type 2 diabetes mellitus	6.86e-07	5.71e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—type 2 diabetes mellitus	6.85e-07	5.71e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	6.84e-07	5.7e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.82e-07	5.68e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	6.8e-07	5.67e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	6.8e-07	5.66e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	6.8e-07	5.66e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	6.78e-07	5.65e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	6.77e-07	5.64e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	6.76e-07	5.63e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	6.74e-07	5.62e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—type 2 diabetes mellitus	6.74e-07	5.62e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	6.7e-07	5.58e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.69e-07	5.57e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.68e-07	5.56e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.61e-07	5.5e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	6.59e-07	5.49e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	6.57e-07	5.47e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—type 2 diabetes mellitus	6.52e-07	5.43e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	6.48e-07	5.4e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—type 2 diabetes mellitus	6.48e-07	5.39e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.48e-07	5.39e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.47e-07	5.39e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.4e-07	5.34e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.37e-07	5.31e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—INS—type 2 diabetes mellitus	6.35e-07	5.29e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—type 2 diabetes mellitus	6.33e-07	5.27e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	6.32e-07	5.27e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—type 2 diabetes mellitus	6.32e-07	5.26e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—type 2 diabetes mellitus	6.32e-07	5.26e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.25e-07	5.21e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3R1—type 2 diabetes mellitus	6.24e-07	5.2e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—type 2 diabetes mellitus	6.24e-07	5.2e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	6.22e-07	5.18e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	6.2e-07	5.16e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	6.16e-07	5.13e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	6.1e-07	5.09e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—type 2 diabetes mellitus	6e-07	5e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.99e-07	4.99e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—type 2 diabetes mellitus	5.98e-07	4.98e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	5.96e-07	4.96e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	5.91e-07	4.92e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	5.9e-07	4.92e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	5.86e-07	4.88e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.86e-07	4.88e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	5.84e-07	4.87e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	5.83e-07	4.86e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.83e-07	4.86e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.83e-07	4.86e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—type 2 diabetes mellitus	5.82e-07	4.85e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	5.81e-07	4.84e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	5.79e-07	4.83e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	5.79e-07	4.82e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	5.75e-07	4.79e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	5.73e-07	4.77e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—type 2 diabetes mellitus	5.71e-07	4.75e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	5.68e-07	4.73e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	5.59e-07	4.65e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—type 2 diabetes mellitus	5.57e-07	4.64e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3R1—type 2 diabetes mellitus	5.57e-07	4.64e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.53e-07	4.61e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.52e-07	4.6e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.5e-07	4.58e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—type 2 diabetes mellitus	5.45e-07	4.54e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—type 2 diabetes mellitus	5.45e-07	4.54e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	5.44e-07	4.53e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	5.44e-07	4.53e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	5.43e-07	4.53e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.39e-07	4.49e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—type 2 diabetes mellitus	5.39e-07	4.49e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	5.36e-07	4.46e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	5.33e-07	4.44e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	5.31e-07	4.42e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	5.22e-07	4.35e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	5.2e-07	4.33e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—type 2 diabetes mellitus	5.14e-07	4.28e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	5.12e-07	4.27e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	5.12e-07	4.27e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—type 2 diabetes mellitus	5.09e-07	4.24e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	5.08e-07	4.23e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	5.08e-07	4.23e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	5.07e-07	4.22e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	5.05e-07	4.2e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	5e-07	4.17e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	4.97e-07	4.14e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.97e-07	4.14e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	4.95e-07	4.12e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—type 2 diabetes mellitus	4.8e-07	4e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	4.8e-07	4e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.74e-07	3.95e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	4.71e-07	3.92e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	4.69e-07	3.9e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	4.65e-07	3.87e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	4.62e-07	3.85e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—type 2 diabetes mellitus	4.58e-07	3.82e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	4.56e-07	3.8e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	4.54e-07	3.78e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	4.49e-07	3.74e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	4.47e-07	3.72e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.43e-07	3.69e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	4.42e-07	3.68e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	4.34e-07	3.62e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	4.34e-07	3.62e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	4.15e-07	3.45e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	3.97e-07	3.31e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	3.89e-07	3.24e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.83e-07	3.19e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	3.82e-07	3.18e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	3.5e-07	2.92e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—type 2 diabetes mellitus	3.39e-07	2.82e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	3.35e-07	2.79e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	3.35e-07	2.79e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	3.31e-07	2.76e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	3.06e-07	2.55e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—type 2 diabetes mellitus	2.87e-07	2.39e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—type 2 diabetes mellitus	2.56e-07	2.13e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	2.5e-07	2.08e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	2.35e-07	1.96e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	2.33e-07	1.94e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	2e-07	1.66e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.54e-07	1.28e-06	CbGpPWpGaD
